{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:05:09Z","timestamp":1793657109155,"version":"4.5.1"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T00:00:00Z","timestamp":1280448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) is an acute, usually monophasic, disorder of the peripheral nervous system that is assumed to be of immune-mediated pathogenesis. However, several clinical features and experimental findings of GBS are uncharacteristic for an immune-mediated disorder and set this condition apart from other disorders with a putative immune-mediated pathogenesis. These features include, among others, the monophasic nature of GBS, the lack of response to immunosuppressive (unlike immunomodulatory) therapy, the absence of a typical association with immunogenetic background and the inability to establish a valid and relevant animal model. We suggest a comprehensive hypothesis for the pathogenesis of GBS that is based on the assumption that the condition is due to a transient (or occasionally chronic) immune deficiency, as in most cases GBS follows an infection with pathogens known to induce immunosuppression. Such infections may be followed by breakdown of immune tolerance and induction of an immune attack on peripheral nerves. Mounting of the immune-mediated assault might be triggered either by the same infective pathogen or by secondary infection. Clearance of the infection and resumption of a normal immune response and tolerance eventually terminate the immune-mediated damage to the peripheral nerves and enable recovery. This hypothesis assumes that the entire sequence of events that culminates in GBS is due to transient exogenous factors and excludes a significant role for inherent host susceptibility, which explains the monophasic nature of the disorder.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04223.x","type":"journal-article","created":{"date-parts":[[2010,7,30]],"date-time":"2010-07-30T14:10:24Z","timestamp":1280499024000},"page":"32-40","source":"Crossref","is-referenced-by-count":13,"title":["Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain\u2013Barr\u00e9 syndrome?"],"prefix":"10.1093","volume":"162","author":[{"given":"I","family":"Steiner","sequence":"first","affiliation":[{"name":"Department of Neurology, Rabin Medical Center, Petah Tiqva"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"D-Pharm Ltd, Kiryat Weizmann Science Park, Rehovot"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Wirguin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,7,30]]},"reference":[{"key":"2021122708483162500_b1","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet"},{"key":"2021122708483162500_b2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1085-9489.2005.0010202.x","article-title":"The immunobiology of Guillain\u2013Barr\u00e9 syndromes","volume":"10","author":"Willison","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"2021122708483162500_b3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2009.05.020","article-title":"Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher\u2013Bickerstaff syndrome)","volume":"215","author":"Yuki","year":"2009","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain\u2013Barre syndrome","volume":"7","author":"Van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"2021122708483162500_b5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jocn.2008.08.033","article-title":"Guillain\u2013Barre syndrome: an update","volume":"16","author":"Vucic","year":"2009","journal-title":"J Clin Neurosci"},{"key":"2021122708483162500_b6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.20743","article-title":"Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis","volume":"58","author":"Sriram","year":"2005","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00019052-200110000-00009","article-title":"Epidemiology of the Guillain\u2013Barre syndrome","volume":"14","author":"Govoni","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"2021122708483162500_b8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMra012493","article-title":"Maternal antibodies, childhood infections, and autoimmune diseases","volume":"345","author":"Zinkernagel","year":"2001","journal-title":"New Engl J Med"},{"key":"2021122708483162500_b9","first-page":"95","article-title":"Recurrent Guillain\u2013Barr\u00e9 syndrome","volume":"44","author":"Das","year":"2004","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"2021122708483162500_b10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/jinf.2001.0917","article-title":"Recurrent Guillain\u2013Barre syndrome as a complication of immune reconstitution in HIV","volume":"44","author":"Makela","year":"2002","journal-title":"J Infect"},{"key":"2021122708483162500_b11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000109575","article-title":"\u2018Hyperacute\u2019 Guillain\u2013Barr\u00e9 syndrome","volume":"59","author":"Steiner","year":"2008","journal-title":"Eur Neurol"},{"key":"2021122708483162500_b12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain\u2013Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"issue":"2","key":"2021122708483162500_b13","first-page":"CD001446","article-title":"Corticosteroids for Guillain\u2013Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122708483162500_b14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00314023","article-title":"Appearance of Guillain\u2013Barr\u00e9 syndrome in patients during corticosteroid treatment","volume":"233","author":"Steiner","year":"1986","journal-title":"J Neurol"},{"key":"2021122708483162500_b15","first-page":"315","article-title":"Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation","volume":"8","author":"Eliashiv","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"2021122708483162500_b16","first-page":"82","article-title":"Guillain\u2013Barr\u00e9 syndrome in an immunocompromised patient and coccidioidomycosis infection","volume":"3","author":"Murali","year":"2006","journal-title":"Rev Neurol Dis"},{"key":"2021122708483162500_b17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/(SICI)1097-4598(199708)20:8<1002::AID-MUS10>3.0.CO;2-X","article-title":"Guillain\u2013Barr\u00e9 syndrome in immunocompromised patients: a report of three patients and review of the literature","volume":"20","author":"Qureshi","year":"1997","journal-title":"Muscle Nerve"},{"key":"2021122708483162500_b18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0022-510X(02)00418-5","article-title":"HIV-associated Guillain\u2013Barr\u00e9 syndrome","volume":"208","author":"Brannagan","year":"2003","journal-title":"J Neurol Sci"},{"key":"2021122708483162500_b19","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1586\/ern.09.43","article-title":"Electrophysiologic and immunopathologic correlates in Guillain\u2013Barre syndrome subtypes","volume":"9","author":"Uncini","year":"2009","journal-title":"Exp Rev Neurother"},{"key":"2021122708483162500_b20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/brain\/awh231","article-title":"Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy","volume":"127","author":"Halstead","year":"2004","journal-title":"Brain"},{"issue":"1","key":"2021122708483162500_b21","first-page":"74","article-title":"The presence of serum antibodies to a panel of ganglioside antigens in the Guillain\u2013Barre syndrome and related disorders","volume":"10","author":"Piven","year":"2005","journal-title":"J Periph Nerv Syst"},{"key":"2021122708483162500_b22","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/77543","article-title":"An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system","volume":"6","author":"Brinkmeier","year":"2000","journal-title":"Nat Med"},{"key":"2021122708483162500_b23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.molmed.2005.12.005","article-title":"Genetic progress towards the molecular basis of autoimmunity","volume":"12","author":"Pearce","year":"2006","journal-title":"Trends Mol Med"},{"key":"2021122708483162500_b24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ACI.0b013e3282f1dc99","article-title":"Genetic determinants of diabetes are similarly associated with other immune-mediated diseases","volume":"7","author":"Duffy","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2021122708483162500_b25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajmg.10725","article-title":"Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion","volume":"113","author":"Korn-Lubetzki","year":"2002","journal-title":"Am J Med Genet"},{"key":"2021122708483162500_b26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-5728(95)00102-8","article-title":"HLA-class II alleles in Guillain\u2013Barr\u00e9 syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection","volume":"62","author":"Rees","year":"1995","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b27","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.4049\/jimmunol.170.6.3074","article-title":"Differential distribution of HLA-DQ beta\/DR beta epitopes in the two forms of Guillain\u2013Barr\u00e9 syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP","volume":"170","author":"Magira","year":"2003","journal-title":"J Immunol"},{"key":"2021122708483162500_b28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jneuroim.2008.08.013","article-title":"Susceptibility to Guillain\u2013Barre syndrome is not associated with CD1A and CD1E gene polymorphisms","volume":"205","author":"Kuijf","year":"2008","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mus.20762","article-title":"Ganglioside mimicry and peripheral nerve disease","volume":"35","author":"Yuki","year":"2007","journal-title":"Muscle Nerve"},{"key":"2021122708483162500_b30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2003.12.004","article-title":"The Guillain\u2013Barr\u00e9 syndrome: a true case of molecular mimicry","volume":"25","author":"Ang","year":"2004","journal-title":"Trends Immunol"},{"key":"2021122708483162500_b31","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1002\/ana.410270716","article-title":"T-cell and macrophage activation in experimental autoimmune neuritis and Guillain\u2013Barr\u00e9 syndrome","volume":"27","author":"Hartung","year":"1990","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.1057","article-title":"Variants of the Guillain\u2013Barr\u00e9 syndrome: progress towards fulfilling \u2018Koch's postulates\u2019","volume":"49","author":"Sheikh","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/122.3.449","article-title":"The distribution of ganglioside-like moieties in peripheral nerves","volume":"122","author":"Sheikh","year":"1999","journal-title":"Brain"},{"key":"2021122708483162500_b34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/jaut.2000.0490","article-title":"Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity","volume":"16","author":"Moran","year":"2001","journal-title":"J Autoimmun"},{"key":"2021122708483162500_b35","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"2021122708483162500_b36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0165-5728(97)00095-7","article-title":"Induction of anti-GM1 ganglioside antibodies by Campylobacter jejuni lipopolysaccharides","volume":"78","author":"Wirguin","year":"1997","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ana.410440610","article-title":"Neuromuscular blockade by IgG antibodies from patients with Guillain\u2013Barr\u00e9 syndrome: a macro-patch-clamp study","volume":"44","author":"Buchwald","year":"1998","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b38","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/brain\/124.5.893","article-title":"Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal","volume":"124","author":"O'Hanlon","year":"2001","journal-title":"Brain"},{"key":"2021122708483162500_b39","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"2021122708483162500_b40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/jnnp.2007.123943","article-title":"Immune responses to myelin proteins in Guillain\u2013Barr\u00e9 syndrome","volume":"79","author":"Makowska","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708483162500_b41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410310407","article-title":"Experimental conduction block induced by serum from a patient with anti-GM1 antibodies","volume":"31","author":"Santoro","year":"1992","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/122.5.807","article-title":"Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro","volume":"122","author":"Paparounas","year":"1999","journal-title":"Brain"},{"key":"2021122708483162500_b43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ana.20173","article-title":"An anti-ganglioside antibody secreting hybridoma induces neuropathy in mice","volume":"56","author":"Sheikh","year":"2004","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-5728(01)00276-4","article-title":"Oral tolerance in experimental autoimmune neuritis (EAN) of the Lewis rat II. Adjuvant effects and bystander suppression in P2 peptide-induced EAN","volume":"116","author":"Jung","year":"2002","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b45","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/mus.880161106","article-title":"Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis","volume":"16","author":"Hahn","year":"1993","journal-title":"Muscle Nerve"},{"key":"2021122708483162500_b46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain\u2013Barr\u00e9 syndrome induced by sensitization with GM1 ganglioside","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b47","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain\u2013Barr\u00e9 syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"2021122708483162500_b48","first-page":"307","article-title":"Keyhole limpet hemocyanin contains Gal(\u03b21-3)GalNAc determinants which are cross-reactive with the T-antigen","volume":"40","author":"Wirguin","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"2021122708483162500_b49","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.4049\/jimmunol.171.7.3585","article-title":"Exogenous administration of gangliosides inhibits Fc epsilon RI-mediated mast cell degranulation by decreasing the activity of phospholipase C gamma","volume":"171","author":"Dr\u00e1berov\u00e1","year":"2003","journal-title":"J Immunol"},{"key":"2021122708483162500_b50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4049\/jimmunol.166.1.72","article-title":"Gangliosides GD1b, GT1b, and GQ1b enhance IL-2 and IFN-gamma production and suppress IL-4 and IL-5 production in phytohemagglutinin-stimulated human T cells","volume":"166","author":"Kanda","year":"2001","journal-title":"J Immunol"},{"key":"2021122708483162500_b51","first-page":"783","article-title":"Immunosuppressive activity of glycosphingolipids. Influence of serum factors on ganglioside inhibition of IL-4-dependent cell proliferation","volume":"12","author":"Molotkovskaya","year":"1999","journal-title":"Membr Cell Biol"},{"key":"2021122708483162500_b52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/jnnp.51.5.613","article-title":"A prospective study of acute idiopathic neuropathy. II. Antecedent events","volume":"51","author":"Winer","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122708483162500_b53","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/WNL.54.3.620","article-title":"Mild forms of Guillain\u2013Barr\u00e9 syndrome in an epidemiologic survey in the Netherlands","volume":"54","author":"Van Koningsveld","year":"2000","journal-title":"Neurology"},{"key":"2021122708483162500_b54","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors and outcome in Guillain\u2013Barr\u00e9 syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology"},{"key":"2021122708483162500_b55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ana.410220322","article-title":"HIV seropositivity in Guillain\u2013Barr\u00e9 syndrome","volume":"22","author":"Berger","year":"1987","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1086\/368311","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with immune reconstitution","volume":"36","author":"Piliero","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2021122708483162500_b57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2006.03.005","article-title":"Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART)","volume":"37","author":"Steininger","year":"2006","journal-title":"J Clin Virol"},{"key":"2021122708483162500_b58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/01.TP.0000148239.00384.F0","article-title":"Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients","volume":"79","author":"Rowshani","year":"2005","journal-title":"Transplantation"},{"key":"2021122708483162500_b59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0966-842X(02)02393-4","article-title":"Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion","volume":"10","author":"Mocarski","year":"2002","journal-title":"Trends Microbiol"},{"key":"2021122708483162500_b60","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/ni1190","article-title":"Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus","volume":"6","author":"Arnon","year":"2005","journal-title":"Nat Immunol"},{"key":"2021122708483162500_b61","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1128\/JVI.02421-05","article-title":"Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment","volume":"80","author":"Frascaroli","year":"2006","journal-title":"J Virol"},{"key":"2021122708483162500_b62","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein\u2013Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"2021122708483162500_b63","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archinte.162.7.837","article-title":"Epstein\u2013Barr viral load assessment in immunocompetent patients with fulminant infectious mononucleosis","volume":"162","author":"Van Laar","year":"2002","journal-title":"Arch Intern Med"},{"key":"2021122708483162500_b64","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(07)70267-3","article-title":"The neurotropic herpes viruses: herpes simplex and varicella-zoster","volume":"6","author":"Steiner","year":"2007","journal-title":"Lancet Neurol"},{"key":"2021122708483162500_b65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","article-title":"Mycoplasma pneumoniae and its role as a human pathogen","volume":"17","author":"Waites","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"2021122708483162500_b66","first-page":"1246","article-title":"Humoral and cellular immunity in children with Mycoplasma pneumoniae infection: a 1-year prospective study","volume":"12","author":"Stelmach","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"2021122708483162500_b67","first-page":"471","article-title":"[A case of Guillain\u2013Barr\u00e9 syndrome (GBS) following human parvovirus B19 infection]","volume":"40","author":"Yamaoka","year":"2000","journal-title":"Rinsho Shinkeigaku"},{"key":"2021122708483162500_b68","first-page":"559","article-title":"Cytomegalovirus infection in patients with systemic lupus erythematosus","volume":"20","author":"Sekigawa","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"2021122708483162500_b69","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1196\/annals.1422.059","article-title":"Epstein\u2013Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report","volume":"1108","author":"Barzilai","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"2021122708483162500_b70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.21316","article-title":"Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis","volume":"63","author":"Sotelo","year":"2008","journal-title":"Ann Neurol"},{"key":"2021122708483162500_b71","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11926-007-0034-x","article-title":"Antiphospholipid antibodies in response to infection","volume":"9","author":"Avcin","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"2021122708483162500_b72","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199812173392501","article-title":"The Guillain\u2013Barr\u00e9 syndrome and the 1992\u20131993 and 1993\u20131994 influenza vaccines","volume":"339","author":"Lasky","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122708483162500_b73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1086\/589624","article-title":"Anti-ganglioside antibody induction by swine (A\/NJ\/1976\/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain\u2013Barr\u00e9 syndrome","volume":"198","author":"Nachamkin","year":"2008","journal-title":"J Infect Dis"},{"key":"2021122708483162500_b74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.38.3.375","article-title":"Immunologic studies of rabies vaccination-induced GBS","volume":"38","author":"Hemachudha","year":"1988","journal-title":"Neurology"},{"key":"2021122708483162500_b75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00002018-200932040-00005","article-title":"Vaccines and Guillain\u2013Barre sundrome","volume":"32","author":"Haber","year":"2009","journal-title":"Drug Safety"},{"key":"2021122708483162500_b76","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3171\/jns.1992.77.5.0694","article-title":"Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors","volume":"77","author":"Quattrocchi","year":"1992","journal-title":"J Neurosurg"},{"key":"2021122708483162500_b77","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.298.14.1685","article-title":"Psychological stress and disease","volume":"298","author":"Cohen","year":"2007","journal-title":"JAMA"},{"key":"2021122708483162500_b78","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11908-996-0033-5","article-title":"Campylobacter enteritis and the Guillain\u2013Barr\u00e9 syndrome","volume":"3","author":"Nachamkin","year":"2001","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"2021122708483162500_b79","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1002\/eji.200737593","article-title":"Regulatory T cells \u2013 a brief history and perspective","volume":"37","author":"Sakaguchi","year":"2007","journal-title":"Eur J Immunol"},{"key":"2021122708483162500_b80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cell.2007.06.033","article-title":"Multistep pathogenesis of autoimmune disease","volume":"130","author":"Goodnow","year":"2007","journal-title":"Cell"},{"key":"2021122708483162500_b81","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.0105-2896.2006.00408.x","article-title":"The role of regulatory T cells in alloantigen tolerance","volume":"212","author":"Aluvihare","year":"2006","journal-title":"Immunol Rev"},{"key":"2021122708483162500_b82","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s00018-004-4233-6","article-title":"Self and non-self discrimination is needed for the existence rather than deletion of autoimmunity: the role of regulatory T cells in protective autoimmunity","volume":"61","author":"Schwartz","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"2021122708483162500_b83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1196\/annals.1361.114","article-title":"Therapeutic T cell-based vaccination for neurodegenerative disorders: the role of CD4+CD25+ regulatory T cells","volume":"1051","author":"Schwartz","year":"2005","journal-title":"J Ann NY Acad Sci"},{"key":"2021122708483162500_b84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10875-008-9239-7","article-title":"Interplay between effector Th17 and regulatory T cells","volume":"28","author":"Awasthi","year":"2008","journal-title":"J Clin Immunol"},{"key":"2021122708483162500_b85","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2","volume":"205","author":"L\u00fcnemann","year":"2008","journal-title":"J Exp Med"},{"key":"2021122708483162500_b86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20376","article-title":"Comparative flow immunophenotypic features of the inflammatory infiltrates of Hodgkin lymphoma and lymphoid hyperplasia","volume":"74","author":"Hudnall","year":"2008","journal-title":"Cytometry B Clin Cytom"},{"key":"2021122708483162500_b87","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jim.2007.01.005","article-title":"The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements","volume":"321","author":"Scheinberg","year":"2007","journal-title":"J Immunol Meth"},{"key":"2021122708483162500_b88","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jneuroim.2007.09.034","article-title":"Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"192","author":"Chi","year":"2007","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b89","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jneuroim.2006.12.002","article-title":"Reduced circulating CD4+CD25+ cell populations in Guillain\u2013Barr\u00e9 syndrome","volume":"183","author":"Pritchard","year":"2007","journal-title":"J Neuroimmunol"},{"key":"2021122708483162500_b90","doi-asserted-by":"crossref","first-page":"26R","DOI":"10.1203\/PDR.0b013e31819e76c7","article-title":"The Treg\/Th17 cell balance: a new paradigm for autoimmunity","volume":"65","author":"Eisenstein","year":"2009","journal-title":"Pediatr Res"},{"key":"2021122708483162500_b91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2004.10.001","article-title":"Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF","volume":"228","author":"Mei","year":"2005","journal-title":"J Neurol Sci"},{"key":"2021122708483162500_b92","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni1328","article-title":"See no evil, hear no evil, do no evil: the lessons of immune privilege","volume":"7","author":"Niederkorn","year":"2006","journal-title":"Nat Immunol"},{"key":"2021122708483162500_b93","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0035-3787(06)75022-6","article-title":"[Severe Guillain\u2013Barr\u00e9 syndrome and pregnancy: two cases with rapid improvement post-partum]","volume":"162","author":"Vaduva","year":"2006","journal-title":"Rev Neurol (Paris)"},{"key":"2021122708483162500_b94","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/10428190410001672149","article-title":"Guillain\u2013Barre syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia","volume":"45","author":"D'Arena","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2021122708483162500_b95","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s12094-006-0126-5","article-title":"Guillain\u2013Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence","volume":"8","author":"Carmona","year":"2006","journal-title":"Clin Transl Oncol"},{"key":"2021122708483162500_b96","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1529-8027.2007.00134.x","article-title":"Guillain-Barre syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma","volume":"12","author":"Terenghi","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"2021122708483162500_b97","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/WNL.41.6.812","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with human immunodeficiency virus infection in Zimbabwe","volume":"41","author":"Thornton","year":"1991","journal-title":"Neurology"},{"key":"2021122708483162500_b98","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/00007890-200105150-00023","article-title":"Guillain\u2013Barr\u00e9 syndrome after solid organ transplantation","volume":"71","author":"El-Sabrout","year":"2001","journal-title":"Transplantation"},{"key":"2021122708483162500_b99","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/00007890-200104270-00026","article-title":"Guillain\u2013Barre syndrome in organ and bone marrow transplant patients","volume":"71","author":"Bulsara","year":"2001","journal-title":"Transplantation"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04223.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/1\/32\/41926107\/j.1365-2249.2010.04223.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/1\/32\/41926107\/j.1365-2249.2010.04223.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:23:17Z","timestamp":1641054197000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/162\/1\/32\/6438668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,30]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,7,30]]},"published-print":{"date-parts":[[2010,9,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04223.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,10]]},"published":{"date-parts":[[2010,7,30]]}}}